Abstract. Members of the TGF-/~ superfamily appear to modulate mesenchymal differentiation, including the processes of cartilage and bone formation. Nothing is yet known about the function of the TGF-#-related factor vgr-1, also called bone morphogenetic protein-6 (BMP-6), and only limited studies have been conducted on the most closely related factors BMP-5, osteogenic protein-1 (OP-1) or BMP-7, and OP-2. Because vgr-1 mRNA has been localized in hypertrophic cartilage, this factor may play a vital role in endochondral bone formation. We developed antibodies to vgr-1, and documented that vgr-1 protein was expressed in hypertrophic cartilage of mice. To further characterize the role of this protein in bone differentiation, we generated CHO cells that overexpressed recombinant murine vgr-1 protein. Western blot analysis documented that recombinant vgr-1 protein was secreted into the media and was proteolytically processed to yield the mature vgr-1 molecule. To assess the biological activity of recombinant vgr-1 in vivo, we introduced the vgr-l-expressing CHO cells directly into the subcutaneous tissue of athymic nude mice. CHO-vgr-1 cells produced localized tumors, and the continuous secretion of vgr-1 resulted in tumors with a strikingly different gross and histological appearance as compared to the parental CHO cells. The tumors of control CHO cells were hemorrhagic, necrotic, and friable, whereas the CHO-vgr-1 tumors were dense, firm, and fibrotic. In contrast with control CHO tumors, the nests of CHO-vgr-1 tumor cells were surrounded by extensive connective tissue, which contained large regions of cartilage and bone. Further analysis indicated that secretion of vgr-1 from the transfected CHO tumor cells induced the surrounding host mesenchymal cells to develop along the endochondral bone pathway. These findings suggest that endogenous vgr-1 acts as an osteoinductive factor during endochondral bone formation.
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U
RtN6 development, a variety of growth and differentiation factors influence cell proliferation, differentiation, and migration. Several secreted peptide growth factors have been shown to mediate these processes, exerting their activities locally in an autocrine or paracrine fashion (reviewed in reference 20). The TGF-B superfamily represents one group of such factors that is particularly important in modulating mesenchymal differentiation (reviewed in references 10, 41) . This family of factors influences pluripotent progenitor cells to differentiate into fibroblasts, adipocytes, myoblasts, chondrocytes, or osteoblasts. Correctly coordinated differentiation of mesenchymal cells references 10, 41) . These proteins can be further subdivided into several groups, based on sequence homology. One of these groups consists of the three "I'GF-/3 isoforms, TGF-/31, -/Y2, and -/~3. Other distinct groups include the activins, inhibins, and Mtillerian inhibitory substance. However, by far the largest group comprises the bone morphogenetic proteins (BMPs) ~, Xenopus vg-1, Drosophila decapentaplegic (dpp), and the more recently cloned polypeptides nodal (59) , dorsalin (3), vgr-2 (22) , and growth/differentiation factors (GDF)-I (27) and . This group has been referred to as the decapentaplegic/vg-l-related proteins (DVR) (30) .
The TGF-~ superfamily, and especially the DVR group, appears to be of considerable importance in bone and cartilage development. Several members of this superfamily have been localized during intramembranous and endochondral bone formation, and they are expressed in a spatially and temporally distinct but overlapping pattern in the differenflating tissue (for an example, see reference 31). The proteins that have been best characterized in terms of their osteoinductive activity are the subgroup consisting of BMP-2 and BMP-4 (reviewed in reference 55), which bear closest homology with the decapentaplegic complex protein dpp of Drosophila (38) . BMP-2 and BMP-4 have the ability to induce osteoblastic differentiation in vitro and ectopic bone formation when injected intramuscularly (for examples, see references 6, 17, 18, 24, 49, 51, 56, 57) , and are at least partially responsible for the osteoinductive activity originally purified from bone (40, 46) .
The largest subgroup of DVR proteins consists of BMP-5 (5), vgr-1 (29) or BMP-6 (5), osteogenic protein-1 (OP-1) (36) or BMP-7 (5), and OP-2 (37), all of which have a high degree of homology to the ancestral 60A protein in Drosophi/a (12) . Although BMP-7 has been shown in an initial study to induce bone formation in vivo (43) and osteoblastic and chondrocytic differentiation in vitro (1, 43) , little is currently known about the functions of the other members of this subgroup and their expression patterns during mammalian development. To define the function of this subgroup in mesenchymal differentiation and especially during endochondral bone formation, we have selected vgr-l/BMP-6 as a prototype for our studies. This eDNA was originally isolated from a murine embryonic eDNA library and was named vgr-l, based on its homology with Xenopus vg-1 (29) . The human and bovine homologues of vgr-1 were subsequently cloned from bone and were named BMP-6 (5), but no bone morphogenetic activity has been reported for this protein. Extensive in situ hybridization analyses have localized vgr-1 mRNA expression to the central nervous system, to various epithelial structures including the suprabasal layer of the epidermis, and, of most relevance to the current studies, to hypertrophic cartilage (21, 31) . Notably, it is the only member of the TGF-B superfamily that has been localized to hypertrophic cartilage, and, as such, vgr-1 protein could be involved in the maturation of hypertrophic cartilage and/or stimulation of osteoblastic differentiation. However, in a recent immunohistochemical localization study, vgr-1 protein was not detected in hypertrophic cartilage, suggesting that there may be translational inhibition of vgr-1 expression in the latter tissue (50).
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In this study, we developed antibodies to vgr-1, and showed that vgr-1 protein was indeed expressed in hypertrophic cartilage. Furthermore, we generated transfected CHO cells that produced recombinant vgr-1 protein, and showed that the protein was proteolytically processed and secreted by these cells. Injection of the vgr-l-expressing CHO cells into the subcutaneous tissue of nude mice resulted in tumors with fibrosis and regions of cartilage and bone. Further analysis indicated that vgr-1 secreted by the injected CHO cells induced the surrounding host mesencbymal cells to differentiate into chondrocytes and osteoblasts. Our data indicate that vgr-1 may represent a vital factor for differentiation along the endochondral bone cascade.
Materials and Methods

Construction of the ~,r-I Expression Vector
To obtain the vgr-I gene, a 780-bp SmaI fragment from the 5' end of the vgr-I eDNA was used as a probe to screen a mouse genomic library in h Charon 4A under high stringency. The library was plated at 50000 pfu/plate, and '~1 x 10 ~ clones were screened. Candidate positive clones from duplicate filter lifts were purified through subsequent rounds of screening. Library plating, probe labeling, phage lifts, and filter hybridizations were carried out as described previously (11) . Restriction fragments of one such phage were suboloned into pUC219 for further mapping, and subsequently sequenced in M13 through standard dideoxy sequencing (44) with Sequenase (United States Biochemical Corp., Cleveland, OH). This analysis led to the identification of the first coding exon of the vgr-1 gene.
For expression studies, the original vgr-1 eDNA (29) was suboloned into the BamHI-EcoRI site of the pRK7 expression vector (53) . To generate the composite full-length vgr-1 eDNA expression vector, we replaced the 5' coding sequence of the original eDNA (29) with an 851-bp BamHI/BspHI genomic fragment that contained 5' flanldn~ DNA and the first coding exon, and then performed a three-part ligation in which this fragment was ligated with the downstream 1551-bp BspHI/EcoRI 3' vgr-1 eDNA fragment and the pRK 7 expression vector that had been digested with BamHI and EcoRI. The resultant plasmid was named pRK7-vgr-1.
Cell Culture and Transfection
CHO cells deficient in the synthesis of dihydrofolate rednctase (dhfr) (47) were propagated in F-12 Ham's nutrient mix (Gibco BRL, Gaithersbuvg, MD) and supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT), 100 U/ml penicillin, and 100 #g/ml streptomycin (both from Giboo BRL). Cells were tmmfeoed with 15 t~g of the pRK7-vgr-1 expression vector and 300 ng of pSV-dhfr DNA (45) using the calcium-phosphate precipitation method (52) . Cells were incubated for 4 h, the medium was removed, and the cells were exposed to a 15% glycerol shock for 1 min. After rinsing twice with PBS, the cells were incubated in supplemented media until they reached confluence, at which time they were split 1:8 and selected in media lacking glycine, hypoxanthine, and thymidine, and supplemented with 5 % dialyzed fetal calf serum. Individual clones were selected after 3 wk, and, after expansion, were screened by Northern blot analysis for expression of vgr-1 mRNA. The integrated plasmid sequences of several positive clones were amplified through culturing in gradually increasing levels of methotrexate, up to 500 nM, thereby generating the CHOvgr-1 cells.
Transient transfections of pRK7-vgr-1 into 293 cells were performed as described previously (15) .
RNA Preparation and Northern Blot Analysis
Total RNA was prepared from cultured cells by lysis with guanidinium isothiocyanate, phenol extraction, and ethanol precipitation, according to standard protocols (7). The RNA was quantitated spectrophotometrically at 260 nm, and was stored at -70°C until use. For Northern blot analysis, 20/~g of total RNA was electrophoresed in a formaldehyde gel in MOPS buffer and transferred to nylon membranes (Gene Screen; New England Nuclear, Boston, MA). The vgr-1 eDNA probe corresponded to the 2.4-kb BamHI/EcoRI eDNA from the pRK7-vgr plasmid, and was radiolabeled using the [32P]dCTP random primer labeling method (Oligolabeling Kit; Pharmacia, Uppsala, Sweden). Hybridization, washing, and autoradiography were performed as described previously (14) .
Cell Growth Rate
CHO or transfected CHO-vgr-1 cells were rinsed with PBS, trypsinized in 0.25% trypsin with 0.02% versene, and diluted in standard media. The cell number was determined using a Coulter counter (Coulter Corp., Hialeah, FL), and 10,000 cells were plated per well on 24-well plates. The cells were grown in standard media with 10% fetal calf serum. FOr analysis of growth rate in the presence of serum, the wells were rinsed, trypsinized, and counted at regular intervals starting 12 h after initial plating. For each time point, three separate wells of cells were individually counted three times, and the cell number was then averaged. FOr analysis of growth rate in the absence of sernm, the freshly plated cells were grown in 10% fetal calf serum for 24 h, then the cells were rinsed three times with PBS and subsequently grown in media supplemented with insulin, transferrin, and selenium (GMS-G supplement; Gibco-BRL). The cells were again grown in triplicate for each time point, and were first counted 24 h after the serum had been withdrawn.
Antibody Production
Oligopeptides were synthesized corresponding to the deduced murine protein sequence at amino acids 141-157 for the pro region antibody and 392-407 for the mature region antibody (see Fig. 2 ). No similar sequences are present in BMP-5 and BMP-7, and therefore no crossreactivity was expected between the vgrol antibodies and these BMPs. An additional cysteine residue was added to the amino terminus of each oligopeptide. The peptides were coupled to keyhole limpet hemocyanin according to the method of Green et al. (16) , and were then mixed in Freund's adjuvant and injected into rabbits (Caltag Laboratories, Inc., South San Francisco, CA). Two animals were injected with each antigen. The initial injection consisted of 150/tg in Freund's adjuvant with subsequent booster doses of 100/tg 3 and 4' wk from the initial injection. The first bleed occurred at 5 wk from the initial injection. A 100-~g injection was given after that bleed, and followup bleeds and injections were each performed at weekly intervals for the next 2 wk, and with a last bleed 1 wk later. There was a 2-wk rest period, then weekly booster injections for 2 wk, followed by a repetition of the above cycle. Antisera was stored at -20°C until use.
Whole antisera was used for Western blot analysis at the dilutions noted below. FOr immunohistochemistry, the antisem were first purified by passage over the appropriate antigen affinity column. The columns were constructed by coupling of the synthetic oligepeptides to Affigel-10 (Bio Red, Laboratories, Richmond, CA) according to manufacturer's instructions. The antisera was purified by mixing with an equal volume of 0.1 M PBS (pH 7.2) and loading onto the appropriate affinity column that had been preequilibrated with this buffer. The column was washed with PBS until the eluant achieved a baseline reading at OD2som. The specific anti-vgr-1 antibodies were then eluted with 40 mM diethylamine (pH 11.4), and exchanged into PBS buffer by passage over a YM-10 membrane (Amicon Corp., Beverly, MA).
Western Blot Analysis
Conditioned media was collected from CHO or CHO-vgr-1 transfectants grown in media in the absence of serum for 24 h. 200-~1 aliquots were lyophilized to dryness, and were resusponded in sample buffer under reducing conditions with 5 %/~-mercaptoethanol. After SDS-PAGE, the samples were Uunsferred to nitrocellulose. Immunoblotting was performed with the enhanced chemiluminesence kit (Amersham Corp., Arlington Heights, IL) according to manufacturer's recommendations. Whole antisera directed against the precursor oligopeptide were used at a 1:1000 dilution, and that derived from the mature oligopeptide was used at a 1:250 dilution. Incubations with the antibodies were performed overnight at 4°C.
Injections into Nude Mice
Homozygous nude, athymic 30-g female mice were obtained from Charles River Laboratories (Wilmington, MA). 5 × 106 CHO or CHO-vgr-1 cells were injected into the right paraspinous area in the lower lumbar region. Cells were prepared for injection by trypsinization, multiple washes with PBS, and resuspension in 0.5 ml of serum-free media per sample. The animals were fed ad libitum and monitored three times per week for the appearance of solid tumors. When the tumors reached 4 cm in largest diameter, or by 4 wk, the animals were euthanized, and the tumors were resected. Portions of the tumors were fixed in 4% paraformaldehyde and embedded in paraffin. The remainder were placed in Tissue Tek OCT compound (Miles Inc., Elkhart, IN) and snap frozen in liquid N2.
Histochemistry and Immunohistochemistry
5-/an paraffin sections were used for all histocbemical analyses, and all staining was performed according to standard procedures (8) .
For immunocytochemistry, cells were grown on tissue culture chamber slides (Nunc Inc., Naperville, IL) to 80% confluence, washed with PBS, fixed in methanol for 10 min, and then stored at -70°C. After several PBS rinses, endogenous peroxidase activity was quenched with 0.3% H202 in 10% methanol for 20 min. The slides were again rimed in PBS and blocked with 3 % BSA in PBS for 30 min at room temperature. The primary antibodies were then applied and incubated overnight at 4°C. The affinity-purified vgr-1 precursor antibody was used at a 1:50 dilution (8/~g/mi). After washes with PBS-0.1% Tween 20, anti-rabbit IgG horseradish peroxidase (Amersham Corp.) was applied at a 1:1000 dilution for 60 rain at room temperature. After further washes, 3-amino-9-ethylcarbazole (AEC) substrate (Dako Co., Carpinteria, CA) was added for 5 to 10 minutes, and then the slides were washed in de-ionized H20, counterstalned with bematexylin, and washed with tap H20.
For analysis of vgT-1 expression in histological sections, we collected mice from gestational day 18.5 embryos, fixed the tissue in 4% paraformaldehyde for 30 minutes, and used 5 ~m sections for immunostaining. The afffiulty-purified mature vgr-I antibody was used at a 1:50 dilution (6 ~g/ml). FOr analysis of the tumors, we used sections from tumors that had been snap frozen in liquid N2 following embedding in Tissue Tek OCT Compound. The collagen type I antibody was an affinity purified goat antibody raised against human and bovine antigens, and the collagen type II antibody was an afffiulty-purified antibody directed against the bovine antigen (both antibodies from Southern Biotechnulogies, Inc., Birmingham, AL). Both antibodies were used at dilutions of 1:1,500. The monoclonal routine osteocalcin antibody was purchased from Biomedical Technologies, Inc. (Stoughton, MA), and was used at a 1:200 dilution.
In Situ Hybridization
To evaluate the expression of dihydrofolate reductase, we used the 548-bp BamHI/BgilI fragment from the 3' untranslated region of the hepatitis B surface antigen gene, which had been incorporated into the 3' region of the dihydrofolate reductase expression unit (45) . This fragment was cloned into the Bluescript vector (Stratagene, La Jolla, CA), and sense and antisense riboprobes were generated with [35S]UTP and T3 and T7 RNA polymerases, respectively, according to the suppliers protocols (Promnga Corp., Madison, WI).
Frozen sections of 5 pm were cut onto "probe-un plus" microscope slides (Fisher Scientific, Pittsburgh, PA), and stored at -70°C. The sections were fixed in paraformaldehyde, acetylated, and prehybridized essentially as described previously (34) . Prehybridization was performed at 50°C in hybridization buffer for 1 h, and then the solution was removed and replaced with the same buffer containing 1 × 106 cpm of riboprobe, and incubated for 16 h at 50°C. Posthybridization washes and RNase treatments were carried out as noted previously (34) . After washes, the slides were dehydrated in increasing concentrations of ethanol with 0.3 M ammonium acetate, air dried, and dipped into Ilford Nuclear Research Emulsion (Cheshire, United Kingdom). Sections were exposed in fight safe boxes at 4°C for 6 d, and then developed in D-19 developer (Eastman Kodak, Rochester, NY). The slides were counterstained in Harris' hematoxylin, and then analyzed under bright-field and dark-field microscopy. and various epithelial structures (50) . However, this antibody failed to detect vgr-1 protein expression in hypertrophic cartilage and in some cell lines that express vgr-1 mRNA, suggesting that there was translational control of vgr-1 expression. Thus, before proceeding with our studies on the role of vgr-1 in endochondral bone formation, we had to determine if vgr-1 protein was even present in hypertrophic cartilage. Towards this end, we developed polyelonal antibodies that specifically recognized both the precursor and mature portions of the murine vgr-1 protein.
Results
Vgr-1 Protein is Expressed in Hypertrophic Cartilage
No purified vgr-1 protein was yet available for antibody production. Instead, we synthesized two oligopeptides from the deduced murine vgr-1 cDNA sequence for use as immunogens. These peptides were selected from regions that have no similarity with the corresponding sequences of the most closely related factors BMP-5 and -7 (5), and thus the resultant antibodies should not cross-react with any related DVR-like factor. Oligopeptides corresponding to amino acids 141-157 in the precursor and 392-407 in the mature portion of the vgr-1 protein (see Fig. 2 ) were synthesized, coupled to keyhole limpet hemocyanin, and were then used as immunogens in rabbits. Antisera exhibited high titers in ELISA assays with these peptides, and reacted in Western blot assays with recombinant vgr-1 protein synthesized by transfected CHO ceils (see below). The whole antisera were then affinity purified using the appropriate immunogenic oligopeptide coupled to Affigel as an affinity matrix, and they yielded antibodies suitable for immunohistochemical analyses of vgr-1 expression.
Immunostaining using the antibody raised against the mature, carboxy-terminal portion of the protein detected vgr-1 protein in the suprabasal layer of the epidermis (see Fig. 1 , A and B), as described previously (50) . In addition, and of importance to our study, we detected vgr-1 protein in hypertrophic cartilage (Fig. 1, A and C) . This staining was predominantly in the extracellular matrix surrounding the hypertrophic chondroeytes. Furthermore, vgr-1 protein localized specifically to regions of hypertrophic cartilage that had undergone mineralization, as shown by corresponding von Kossa staining in an adjacent tissue section (Fig. 1 D) . Thus, vgr-1 protein appeared in the latter stages of hypertrophic cartilage differentiation. The negative control, performed with substitution of rabbit IgG as the primary antibody, resulted in no such staining pattern, demonstrating the specificity of the vgr-1 immunostaining. When using the antibody raised against the precursor segment peptide, vgr-1 protein was again detected in skin, but only ,~ery weak immunostaining was apparent in hypertrophic cartilage (data not shown).
Expression of Recombinant Vgr-1 Protein by Tmnsfected Cells
The expression of vgr-1 in the hypertrophic cartilage suggested that it may play a role in the maturation of the hypertrophic ehondroeytes and/or may stimulate new bone formation. However, to date, ,no natural vgr-1 protein has been purified, and thus nothing is known about its physiological activities. Therefore, to determine the role of this factor in endoehondral bone formation, it was necessary to first produce recombinant vgr-I protein.
Initially, the published vgr-1 eDNA (29) was inserted downstream of the cytomegalovirus promoter in the expression vector pRK7. However, transfections of this expression vector into 293 cells did not result in detectable vgr-1 protein expression. Inspection of the predicted vgr-1 polypeptide sequence showed that the NH2-terminal sequence did not comply well with the consensus rules of von Heijne for signal peptides (48) , and we suspected that our eDNA clone was partial length. We subsequently screened a murine genomic library with a 5' vgr-1 eDNA probe, and identified an upstream exon that contained the 5' untranslated region, a translational initiation consensus sequence (26) , and a canonical signal peptide sequence (48) . Primer extension experiments, using RNA from PYS cells, verified that this sequence represented the 5' end of the vgr-1 mRNA (Kobrin, M. S., unpublished data). Furthermore, the polypeptide sequence deduced from this genomic fragment now had a high degree of sequence similarity with the NH2 terminus of bovine BMP-6 (5). In retrospect, we believe that the different 5' end in the published mouse vgr-1 sequence (29) resulted from a eDNA artifact that is likely related to the high G-C content of this sequence. We then constructed a composite vgr-1 expression vector in pRK7 by ligating a 5' 851-bp BamHI-BspHI genomic fragment onto the corresponding downstream vgr-1 eDNA fragment (29) . Transient transfections of the pRK7-vgr-1 plasmid into 293 cells and metabolic labeling of the proteins now resulted in the appearance of an overexpressed protein consistent in size with the vgr-1 protein (data not shown). The full-length cDNA sequence encoding the 510-amino acid murine vgr-1 polypeptide is shown in Fig. 2 .
To produce a stable source of recombinant vgr-I protein, we cotransfected pRK7-vgr-1 and a dihydrofolate reduetase expression plasmid into CHO ceils, selected several clones expressing high levels of vgr-1 mRNA, and amplified its expression in the presence of increasing concentrations of methotrexate. As shown in Fig. 3 A, Northern blot analysis revealed a high level of vgr-1 mRNA in one such clone grown in 500 nM methotrexate. In contrast, CHO cells transfected with dihydrofolate reductase alone did not express vgr-1 mRNA. Immunostaining using the vgr-1 antiserum also showed specific staining of the vgr-1 mRNA-overproducing CHO-vgr-1 cells, indicating the synthesis of vgr-1 protein (Fig. 3 C) . The parental CHO cells exhibited no such staining, again indicating lack of vgr-1 expression.
To assume biological activity, members of the TGF-B superfamily must enter the secretory pathway and undergo a proteolytic cleavage that separates the precursor region from the biologically active carboxy terminal domain. To determine if such processing occurs in the CHO-vgr-1 stable transfectants, we collected conditioned media produced by these cells and performed Western blot analyses using our vgr-1 antisera (Fig. 3 B) . After denaturing gel electrophoresis under reducing conditions and Western analysis, each antiserum recognized two protein bands from the media of transfected cells, but not of the nontransfected cells. The larger protein band had a size of "~69 kD, and it reacted in Western blots with antisera raised against both the precursor and mature vgr-1 segments. This band most likely corresponded to the uncleared vgr-1 precursor polypeptide, given its dual antibody reactivity and its size. Two lower protein bands were seen as well: a 46-kD protein that reacted only with the antibody specific for the vgr-1 precursor segment, and a 23-kD protein that reacted with the antibody for mature vgr-1. These proteins thus corresponded to the two cleavage products expected after proteolytic processing of the vgr-1 precursor. These cells secreted ~2 #g/ml per 24 h of the recombinant factor, and based on these Western analyses, ,x,50% of the secreted protein had been proteolytically processed. The 69-and 46-kD bands each migrated as a subtie doublet (Fig. 3 B) , which was most apparent in lower percentage polyacrylamide gels (data not shown). This may have been caused by variations in glycosylation.
Effects of vgr-1 on CHO Cells in Culture
To determine the effect of vgr-1 overexpression on these cells, we characterized changes in morphology, growth rate, and collagen synthesis. No significant difference in cell size, shape, or adherence was noted between CHO and CHO-vgr-1 cells (Fig. 3 C) . However, in comparison with the parental CHO cells, CHO-vgr-1 cells had a significantly slower rate of cell proliferation both in the presence and absence of seexample, see reference 13), and we reasoned that the conrum (Fig. 4 ). There were no differences in levels of exprestinuous release of recombinant vgr-1 by the tumor cells sion of collagen I and II, as assessed by immunocytochemiswould allow us to evaluate the biological activity of vgr-1 in try and Northern blot analysis (data not shown), vivo. This approach would thus not necessitate the purification of recombinant vgr-1, but would rely on a continuous re-
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into the extracellular matrix. To this end, we injected CHO To evaluate the effects of vgrA in vivo, we injected the vgror CHO-vgr-1 cells into the fight paraspinous area in the 1-expressing CHO cells subcutaneously into nude mice.
lower lumbar region of nude, athymic mice. Five animals Previous studies had shown that CHO cells form localized were injected with the parental cells, and five with the stable tumors when injected subcutaneously into nude mice (for an transfected CHO-vgr-1 cells. One animal from each group died from nonspecific causes before visible tumor growth occurred. After 2 wk, tumors were visible in all mice injected with either cell line. In concordance with the in vitro growth rate studies, the tumors produced by the parental cells grew faster than those from the vgr-l-transfected CHO cells (data not shown). After 1 mo, or by the time the tumors reached 4 cm in largest diameter, the animals were killed and autopsies were performed. The tumors produced by both cell types were well localized and encapsulated. However, the tumors had striking differences in gross morphology (Fig. 5) . The parental cells produced tumors with a convoluted surface, and they were hemorrhagic, necrotic, and friable (Fig. 5 A) . In contrast, the CHO-vgr-1 tumors did not have a significant hemorrhagic component, had a smooth surface, and were quite dense, firm, and fibrotic (Fig. 5 B) .
Histological examination of these tumors further highlighted the differences noted in the gross morphology. Hematoxylin and eosin staining of the CHO tumors showed nests of tumor cells surrounded by necrotic debris, as well as red and white blood cells (Fig. 6 A) . Similar nests of tumor cells were also seen in the CHO-vgr-1 tumors, but there were no significant areas of necrosis. Moreover, the tumor ceils were encompassed by regions of fibrosis, with significant expansion of surrounding connective tissue (Fig. 6 B) . The tumors induced by the CHO-vgr-1 cells appeared to contain a well-developed vasculature, which in turn supported the growth and development of an organized tissue mass.
Bone and Cartilage Formation in rgr-1 Expressing CHO Tumors
Further histological examination of hematoxylin-eosinstained tissue sections from CHO-vgr-1 revealed regions of cartilage and bone tissue within portions of the mesenchyme in and around the tumors, accounting for ~20% of the tumor mass (Fig. 6 C) . These areas contained varying amounts of cartilage and bone, with some consisting solely of cartilage, others containing a mixture of both cartilage and bone, and finally, areas corresponding solely to bone. No bone and cartilage tissue was observed in any of the tumors derived from the parental CHO cells. To further characterize these areas of bone and cartilage formation, we performed several histochemical and immunohistochemical staining procedures. In Fig. 7 , the tumor sections were stained with Alcian blue, which binds to mucopolysaccharides found in cartilage. The CHO tumor sections did not stain with Alcian blue, but only with the counterstain, whereas the CHO-vgr-1 tumors contained extensive regions of blue staining (Fig. 7, A and B) . At higher magnification, these areas appeared morphologically as chondrocytes or hypertrophic chondrocytes (Fig. 7 C) . An adjacent section was stained by the von Kossa method, and some of these same areas stained black, indicating regions of mineralization. Thus, such areas contained hypertrophic cartilage that had mineralized; if this tumor had been incubated longer in vivo, then this area would presumably have been replaced by bone.
To confirm areas of bone formation within the CHO-vgr-1 tumors, we analyzed different sections using the yon Kossa and trichrome staining methods. As shown in Fig. 8 , CHOvgr-1 tumors, but not tumors derived from the parental CHO cells, had areas that stained positively in regions that appeared morphologically as trabecular bone. At a higher magnification, we noted the presence of osteoblasts, osteocytes, and osteoclasts within such areas of trabeeular bone.
The regions of cartilage and bone were further defined with immunohistochemical analyses for collagen II, which is specifically deposited in cartilage, and for collagen I and osteocalcin, proteins associated with bone. Portions of the CHO-vgr-1 tumor stained specifically with the collagen II antibody, with such staining apparent in cartilage matrix,but not in areas of apparent bone formation (Fig. 9 A) . No collagen II staining was detected in the CHO tumors. Other areas that appeared histologically as bone were stained with antibodies for both collagen I and osteocalcin (Fig. 9, B and C) . No such dual collagen I and osteocalcin staining was seen in any region of the CHO tumors. Collagen I staining was not confined to bone in the CHO-vgr-1 tumors, but was also noted within areas of surrounding connective tissue; widespread staining was also noted within the CHO tumors in regions of necrotic debris. Finally, CHO-vgr-1 tumors also had regions that stained with all three antibodies, indicative of cartilage adjacent to bone tissue (Fig. 9 D) . Collectively, these findings suggest that there had been a recapitulation of endochondral bone formation within these tumors, in which a cartilage template formed initially and was eventually replaced by bone.
We postulated that the vgr-1 secreted by the transfected CHO cells had induced mesenchymal cells of the host animal to differentiate into bone and cartilage. Indeed, mesenchymal cells are known to differentiate into chondroblasts and osteoblasts, whereas CHO cells are not known to differentiate. To prove this hypothesis, we designed a riboprobe for in situ hybridization to distinguish injected CHO cells from host mouse cells. Although both the host and transfected CHO cells expressed endogenous dhfr mRNA, the CHO cells also overexpressed an additional dhfr mRNA derived from the transfected expression vector (45) . This latter transcript contained a unique 3' untranslated region derived from the hepatitis B surface antigen gene. This region served as a riboprobe to specifically identify CHO cells within the tumor samples. As seen in Fig. 10 A, the antisense riboprobe hybridized intensely to the nests of CHO- vgrol tumor cells, but did not react with the cells in the cartilage and bone tissue and surrounding mesenchyme at the tumor periphery. Therefore, the cells within these tissues must have arisen from mesenchymal cells of the host animal that had been incorporated into the tumor. A low, uniform background of nonspecific hybridization was seen using the sense strand probe as a negative control (Fig. 10, C and D) . This conclusion was further strengthened by the positive immunostaining for osteocalcin (Fig. 9) . This antibody recognizes only mouse but not hamster osteocalcin, confirming that the bone tissue must have originated from mouse.
Discussion
Little is currently known about the function of a distinct subgroup of the TGF-~ superfamily consisting of BMP-5, vgr-1/ BMP-6, OP-1/BMP-7, and OP-2. We have focused on vgr-1/ BMP-6 as a prototype member of this subgroup. The previous finding that vgr-1 mRNA is the only TGF-B superfamily member localized to hypertrophic cartilage suggests that it may play a pivotal role in the transition of cartilage to bone during endochondral bone formation. We report here the generation of vgr-l-specific antibodies and the subsequent immunohistocbemical localiz~ttion of vgr-1 protein to hypertrophic cartilage. Furthermore, we produced stably transfected CHO cells expressing recombinant vgr-1 protein at high levels. Finally, we injected the vgr-l-expressing CHO cells into mice to evaluate the effects of continuous release of vgr-1 in vivo. In contrast to the nontransfected cells, the minors formed by vgr-l-expressing cells contained extensive areas of fibrosis, with bone and cartilage formation in a pattern that seemed to mimic endochondral bone formation. 
Vgr-1 Expression in Hypertrophic Cartilage
Previous studies have localized vgr-1 expression in the developing mouse using both in situ hybridization and immunohistochemistry (21, 29, 50) . The former studies established the expression of vgr-1 mRNA in the central nervous system, suprabasal layer of the epidermis and other epithelial structures, and in hypertrophic cartilage. However, using immunohistochemistry, vgr-1 protein was found only in the central nervous system and epithelial structures, but not in hypertrophic cartilage, leading to the suggestion that the mRNA may not be translated in the latter tissue (50) . We now report that vgr-1 mRNA is indeed translated into protein in hypertophic chondrocytes, as assessed by immunohistochemical staining using our vgr-1 antibody. The antibody staining is highly localized in the matrix surrounding the hypertrophic chondrocytes. This staining pattern strongly suggests that the secreted vgr-1 has a very limited diffusion range and that the hypertrophic cartilage matrix serves as a reservoir for this TGF-/~ superfamily member.
Vgr-1 was immunolocalized to hypertrophic cartilage solely using an antibody against the mature, carboxyterminal portion of the protein. In contrast, both Wall et al. (50) and ourselves were unable to detect protein expression in this tissue using an antibody directed against the vgr-1 precursor segment. The reason for this inability remains unclear. One possibility is that the precursor region has acquired an altered conformation, either naturally or as a result of the treatment procedure, that renders it inaccessible to the antibody. If this were the case, then this modification must be different from that in epithelial structures and in the central nervous system, where the vgr-1 precursor antibody was used successfully. Alternatively, the vgr-1 precursor segment may be proteolytically degraded in hypertrophic cartilage. This would resemble the proteolytic activation of TGF-/5'I in situ after irradiation, which is accompanied by a strong decrease in immunostaining using a precursor-specific antibody (2). Such vgr-1 precursor segment degradation could, in turn, provide higher accessibility of mature vgr-1 for its receptor, as in the case of TGF-B.
Recombinant Expression of vgr-1 Protein and Biological Activity In Vivo
To evaluate the biological functions of murine vgr-1, we generated an efficient expression plasmid to overexpress recombinant protein. CHO cells stably transfected with this vector synthesized and secreted high levels of recombinant vgr-1 protein, approximately half of which had undergone the predicted proteolytic cleavage. The transfected cells grew slower than the parental cells, but otherwise exhibited no significant differences when characterized in vitro.
To assay the biological activity of vgr-1 in vivo, we introduced the CHO-vgr-1 transfectants directly into mice via a subcutaneous injection, rather than first purifying recombinant protein from conditioned media of the CHO-vgr-1 cells. Previous studies have documented that CHO cells form localized tumors when injected subcutaneously (13), and we reasoned that the transfected cells would act as a depot source of vgr-1 by continuously releasing the recombinant protein within the tumor. As expected, injection of the CHOvgr-1 stable transfectants in nude mice induced tumor formation, as did the parental cells. However, the CHO-vgr-1 tumors showed a striking increase in surrounding connective tissue and exhibited bone and cartilage formation. Some areas showed only cartilage or trabecular bone; others contained bone intimately associated with adjacent areas of cartilage, or contained areas of mineralized cartilage. Taken collectively, these findings suggest recapitulation of endochondral bone formation, in which a cartilage template is first formed, and is later replaced by mineralized bone.
Another fundamental difference between the tumors induced by the CHO cells as opposed to the CHO-vgr-1 transfectants was that the parental cells produced tumors lacking any organized vascular supply. Thus, overgrowth of these cells resulted in hemorrhagic, necrotic debris, and the tumors were unable to support development of an organized tissue mass. By contrast, the CHO-vgr-1 cells formed tumors with a well-delineated vascular supply, and thereby supported development of well-organized tumor masses, with profusion of connective tissue and differentiation of cartilage and bone. During endochondral bone formation, angiogenesis in hypertrophic cartilage is critical for mineralization and subsequent bone formation. The endogenous localization of vgr-1 to the site of angiogenesis in hypertrophic cartilage suggests that this factor may mediate new vessel formation. The cellular elements of fibrosis and endochondral bone formation within the CHO-vgr-1 tumors did not appear to have arisen directly from the CHO cells, but instead from the effects of secreted vgr-1 on surrounding host mesenchymal cells. Several lines of evidence support this hypothesis. First, the connective tissue, cartilage, and bone did not hybridize with a riboprobe that specifically identified the transfected CHO cells. Second, CHO cells are not known to differentiate in vitro or in vivo, making it unlikely that the vgr-l-transfected CHO cells differentiated into osteoblasts or chondrocytes. In fact, the transfected cells exhibited no such differentiation when evaluated in vitro. Third, the bone matrix within the CHO-vgr-I tumors stained positively using a monoclonal antibody specific for mouse osteocalcin that does not cross-react with rat or hamster osteocalcin, further substantiating our conclusion that the ectopic bone did not originate from hamster cells. Finally, conditioned media from CHO-vgr-1 cells, but not from CHO cells, also induced ectopic bone formation when injected intramuscularly (Kirk, M., and S. E. Gitelman, unpublished results).
Vgr-1 secreted by the CHO-vgr-1 tumors appeared to have acted only locally within these animals. We have not devel-oped an assay to measure serum levels of vgr-1, and thus have not formally tested if these animals contained significant circulating levels of this factor. However, analysis of long bones near the site of the tumor showed no changes as compared to those of the control animals, and extensive autopsies revealed no significant changes in any other major organs.
Possible Mechanisms of Vgr-1 Action
Our findings indicate that recombinant vgr-1 protein was sufficient to induce fibrosis and bone and cartilage formation in vivo. Yet, the complexity of such an in vivo study makes it difficult to pinpoint the specific primary actions directly attributable to vgr-1, as opposed to secondary actions mediated through other factors. One important function of vgr-1, at least in the context of this study, may be as a chemoattractant to bring various cell types to the tumor, including mesenchymal precursors. Alternatively, vgr-1 may act as a mitogen to increase the number of various host cells already present in or near the tumor. In fact, several other members of the TGF-/~ superfamily can serve as chemoattractants or mitogens for a variety of cell types, including mesenchymal cells, fibroblasts, osteoblasts, neutrophils, monocytes, epithelial cells, and endothelial cells (for examples, see references 19, 39, 42, 58) . The most widely studied factor from this standpoint has been TGF-/31. Injection of recombinant TGF-/31 into newborn mice and chicken chorioallantoic membrane induces a granulation tissue response, with inflammation, fibrosis, and angiogenesis (42, 58) . The hypercellular lesions in the chicken study resulted not from cellular proliferation, but from enhanced cell migration through chemotaxis (58) . Only limited studies have been conducted with the BMPs, with BMP-3 and BMP-4 chemotactic for monocytes in vitro (9) . Further studies are needed to determine if vgr-1 also serves as a chemoattractant and/or mitogen, and if vgr-l's actions in this regard are distinguishable from that of other members of the TGF-/~ superfamily. Vgr-1 does not alter the growth rate of two pluripotent mesenchymal cell lines in vitro, suggesting that it may not function as a mitogen in vivo (Gitelman, S. E., J. Q. Ye, and R. Derynck, unpublished results).
The influx of additional host cells into the tumor site adds another layer of complexity in characterizing the primary actions of vgr-1. Each of these cell types may release additional factors into the tumor area, such as other TGF-/3 superfamily members, local growth factors, cytokines, or various extracellular matrix proteins. Vgr-1 may act in a paracrine fashion to stimulate production and release of such factors from these neighboring host cells, and may also act in concert with these factors to induce the fihrotic changes and endochondral bone formation noted within the CHO-vgr-1 tumors.
Role of TGF-[3 Superfamily in Endochondral Bone Formation
Several members of the TGF-/3 superfamily have now been shown to induce endocbondral bone formation when injected in vivo. TGF-/31 and TGF-/32 induce endochondral bone formation when introduced subperiosteally or at a fracture site, but not at a site that is not anatomically connected to bone (4, 23, 32, 35) . In contrast, BMP-2, -3, -4, -7, and now vgr-1 have the ability to induce ectopic bone formation when injected intramuscularly or subcutaneously (17, 28, 43, 51, 54) . Such findings suggest that these BMPs may act on a less differentiated mesenchymal precursor than TGF-~ during endochondral bone formation. The findings also imply functional redundancy among these factors, yet specificity appears to reside in the spatially and temporally distinctive patterns of their expression (for an example, see reference 31) .
In all other studies, a recombinant factor has been introduced in vivo as a purified protein delivered within an inert carrier. Our study is the first to have been conducted with direct injection of CHO cells that continuously release recombinant protein. As a result, comparison of vgr-rs potency with that of the other TGF-/~ related factors is not yet possible, and awaits purification of recombinant vgr-1 from conditioned media.
Definition of the specific role of individual TGF-/~ superfamily members in endochondral bone formation awaits more refined studies, both in vitro and in vivo. The present study entailed overexpression of vgr-1 in an ectopic location, and demonstrated that vgr-1 had the ability to initiate mesenchymal differentiation along the endochondral bone pathway. To further define the function of this factor during normal bone and cartilage development, it will be important to manipulate the expression of vgr-1 and its receptor within hypertrophic cartilage, vgr-rs endogenous site of production.
